Home
Scholarly Works
Buprenorphine/naloxone access for people with...
Journal article

Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation

Abstract

People with opioid use disorders are overrepresented in correctional facilities, and are at high risk of opioid overdose. Despite the fact that buprenorphine/naloxone is the first line treatment for people with opioid use disorder, there are often institutional, clinical, and logistical barriers to buprenorphine/naloxone initiation in correctional facilities. Guided by the knowledge-to-action framework, this knowledge translation project focused on synthesizing knowledge and developing a tool for buprenorphine/naloxone initiation that was tailored to correctional facilities, including jails. This information and tool can be used to support buprenorphine/naloxone access for people in correctional facilities, in parallel with other efforts to address barriers to treatment initiation in correctional facilities.

Authors

Regenstreif L; Sadik M; Beaulieu E; Bodkin C; Kiefer L; Guenter D; Lee PWP; Kouyoumdjian FG

Journal

Health & Justice, Vol. 10, No. 1,

Publisher

Springer Nature

Publication Date

December 1, 2022

DOI

10.1186/s40352-022-00174-w

ISSN

2194-7899

Labels

Fields of Research (FoR)

Sustainable Development Goals (SDG)

Contact the Experts team